Protagenic Therapeutics announces private placement of up to $5M to advance PT00114 into first US clinical trial

Protagenic Therapeutics announced a private placement financing providing $1.5 million in upfront gross proceeds, with potential for an additional $3.5 million through milestone-linked warrants. Funds will complete IND-enabling activities for lead candidate PT00114 and initiate a planned Phase 1/2a trial for Generalized Anxiety Disorder.

Detected & updated continuously · Source: Nebula